Welcome to our dedicated page for Cellebrite Di SEC filings (Ticker: CLBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cellebrite DI Ltd. (NASDAQ: CLBT) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a foreign private issuer. Cellebrite files an annual report on Form 20-F and current reports on Form 6-K, which include press releases on quarterly financial results, shareholder meetings and other material information. These filings are incorporated by reference into registration statements on Form S-8 for equity compensation plans and Form F-3 for shelf registration, as noted in recent 6-K reports.
For investors analyzing CLBT, the annual Form 20-F is a key source for detailed information on the company’s digital investigation and intelligence business, risk factors, segment information, use of artificial intelligence, international operations and regulatory environment. Periodic Form 6-K filings furnish earnings releases that summarize revenue trends, subscription metrics such as annual recurring revenue, and non-GAAP measures like adjusted EBITDA, along with commentary from management on strategy and market conditions.
This page also surfaces filings that document corporate governance and shareholder actions, such as reports on annual general meetings where shareholders vote on proposals in accordance with Israeli Companies Law and the company’s articles of association. These filings can help readers understand board composition, equity plans and other governance matters.
Stock Titan enhances access to these documents with AI-powered summaries that explain the core points of lengthy filings, helping users interpret complex financial tables, risk disclosures and legal language. Real-time updates from EDGAR ensure that new 6-Ks, the latest 20-F and any registration statements become available quickly. Users can also review insider-related and equity compensation information through the company’s registration statements and related disclosures, using this page as a starting point for deeper analysis of CLBT’s regulatory record.
Cellebrite DI Ltd. (CLBT) filed a Form 144 reporting a proposed sale of 34,151 ordinary shares on 09/22/2025 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $601,399.11 and 245,691,023 shares outstanding. The shares were acquired as 107,008 Restricted Stock Units on 09/19/2025 from Cellebrite DI Ltd. and were received as compensation. The filing indicates no reported sales by the seller in the past three months. Several filer identification fields in the public extract (CIK/CCC and contact details) are blank in the provided text.
Form 144 notice for proposed sale of securities by an insider or affiliate. The filing reports an intended sale of 25,810 shares of Common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $454,514.10. The shares are listed on NASDAQ and the approximate sale date provided is 09/22/2025. The shares were acquired as restricted stock units from the issuer on 02/15/2023, and no related securities sales were reported in the prior three months. Several filer and issuer identification fields are left blank in the supplied content.
Cellebrate DI Ltd. reports that shareholders approved all proposals presented at its annual general meeting of shareholders held on September 19, 2025. These proposals were adopted by the requisite majority in accordance with Israeli law and the company’s articles, as outlined in the proxy statement previously provided to investors.
The meeting had strong participation, with 188,039,771 ordinary shares represented, equal to approximately 76.82% of issued and outstanding ordinary shares as of the record date. This report is also incorporated by reference into Cellebrite’s existing registration statements on Form S-8 and Form F-3.
Cellebrite DI Ltd. (CLBT) filed a Form 144 reporting a proposed sale of 27,166 common shares with an aggregate market value of $481,313.61. The shares represent a small fraction of the 244,469,106 shares outstanding and are scheduled for sale on or about 09/19/2025 on NASDAQ. The shares were acquired as restricted stock from the issuer on 02/14/2025, 05/14/2025, and 08/14/2025, totaling 27,166 shares. The filing also discloses a sale during the past three months of 12,878 shares on 09/11/2025 for gross proceeds of $225,743.61. The document includes the required signer representation that no undisclosed material adverse information exists.